Nipocalimab pivotal Phase 3 trial demonstrates sustained
First FcRn blocker to demonstrate superiority in Myasthenia Gravis - Activities of Daily Living score (MG-ADL) a over placebo when ...
Read moreFirst FcRn blocker to demonstrate superiority in Myasthenia Gravis - Activities of Daily Living score (MG-ADL) a over placebo when ...
Read moreSingle administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also ...
Read moreRESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for ...
Read morePatients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.